Artificial intelligence (AI) is becoming a foundational layer in health technology, reshaping how care is delivered, managed and improved across the entire health system. AI enables the analysis of vast and complex health data sets that are beyond human capacity, turning data into actionable insights. This capability supports earlier diagnosis, more precise treatments and more efficient use of resources, while also helping health systems respond to rising demand, workforce shortages and cost pressures.

AI in health tech has also become a key enabler for several medtech innovators within the EIC Scaling Club. Although they represent different sectors of healthcare, they have each found a way to achieve their ambitious goals with the help of AI innovation. 

Let’s have a closer look at Club members leveraging AI to drive breakthroughs with the potential to benefit patients and society at large.

AI in diagnostics

One major area of innovation is clinical decision support and diagnostics, where AI is used to analyse medical images, pathology slides, genomics and electronic health records to assist clinicians in detecting diseases and selecting treatments. 

Several Club members from the Cardiovascular Therapies market group are seeking novel approaches to detecting diseases more quickly and efficiently. For example, Lithuanian medtech innovator Ligence is transforming how echocardiography exams are performed, empowering clinicians to diagnose faster and more precisely with the help of AI. 

As Ligence’s CEO Arnas Karužas explained in our earlier interview, Ligence’s software assists clinicians by automating cardiac measurements and report generation, so cardiologists can save time, improve accuracy, and provide better care for more patients. Ligence’s AI is built and refined in daily collaboration with cardiologists to ensure it fits seamlessly into real-world workflows. Arnas told us:

“Since [cardiovascular diseases are] the #1 killer in the world, we want to make cardiac diagnostics easier, simpler for doctors, and more accessible for patients. At its core, we want to transform cardiovascular diagnostics through AI-powered automation.”

Ligence has achieved several major milestones that underscore both its scientific credibility and market readiness. Its product became the first ultrasound AI to receive the CE mark under the new European Medical Device Regulation (MDR), complemented by ISO certifications that ensure data security and quality standards.

Another member of our Cardiovascular Therapies market group, contextflow, is a Vienna-based healthcare scale-up developing AI solutions to detect conditions like lung cancer and interstitial lung disease earlier and more efficiently. contextflow's AI solutions directly address the shortage of lung cancer screening personnel, scanners and radiologists by enabling faster, more accurate analysis of chest CT scans. 

While AI technologies in healthcare hold huge potential for society, scaling them involves numerous challenges. As Julie Sufana, contextflow's Chief Marketing Officer, told us in an earlier interview: 

"AI in radiology sounds very attractive to the outside world, but is actually very challenging to the people working in it." 

Despite the hurdles, contextflow was one of the first radiology AI software devices to receive CE mark under the new European MDR certification – a major achievement for an early-stage company.

Spanish Amadix is another diagnostics company within the EIC Scaling Club – it specialises in early cancer detection through liquid biopsy and AI. This biotechnology scale-up – a member of our New Biotech Platforms market group – develops blood-based diagnostic tests designed to identify cancer at its earliest and most treatable stages, with a focus on colorectal, pancreatic and lung cancers.

To reach its goal, Amadix develops AI-driven algorithms, combining medical history and individual lifestyle data to identify and analyse hidden risks. In an interview for the EIC Scaling Club’s blog, Pauline Dapena-Cherry, Amadix’s U.S. Chief Operating Officer, said these technologies enable the definition of new screening populations beyond age-based criteria, supporting earlier detection and improved patient quality of life.

Personalised medical care

Moving beyond diagnostics, a closely related domain is precision and personalised medicine, where machine learning models integrate genetic, clinical and lifestyle data to tailor therapies to individual patients.

CheckPoint Care stands out here. The Bulgaria-based telemedicine company, a member of our Cardiovascular Therapies market group, is reshaping how remote patient care is delivered.

The company combines advanced wearable technology, AI-driven analytics, and clinical supervision to make high-quality home care available to everyone, round the clock. 

As Kaja Vidic, the company’s Chief Business Development Officer, told us in an interview, at the core of CheckPoint Care’s solution lies a three-pillar system that connects patients, clinicians, and technology. 

The wearable device captures real-time electrocardiography (ECG) and physiological data, including up to 100 vital parameters. This data is continuously transmitted to an AI-powered online modular platform. There, the system calculates 10,000 digital biomarkers, generating a personalised digital twin of each patient – a virtual representation of the patient's physiological state. This digital model enables predictive insights and supports proactive clinical decision-making.

CheckPoint Care’s gathered data is continuously monitored at the Virtual Care Center with a dedicated team of clinicians conducting trend analyses, detecting deteriorations, and supporting treating physicians in real time.

Drug development

AI is also driving progress in drug discovery and development, accelerating target identification, molecule design and clinical trial optimisation, significantly reducing time and cost compared to traditional approaches.

This is the domain where Arctic Therapeutics, our New Biotech Platforms group member from Iceland, operates. The company harnesses the power of applied genomics, coupled with AI, to accelerate drug development and develop new treatments for diseases such as Alzheimer's, acne, and asthma. 

Arctic Therapeutics specialises in using bioinformatic approaches and AI to eliminate significant risks and enormous costs associated with traditional drug development. Thus the scale-up enables healthcare operators to help patients understand their genetic results and how these results guide individual therapies.

Arctic Therapeutics product portfolio targets diseases with limited treatment options, ranging from rare and common forms of dementia to inflammatory skin diseases and autoimmune disorders, with the aim of delivering meaningful impact for patients.

The company’s work has been recognised by international investors – in 2025, Arctic Therapeutics closed a €26.5 million oversubscribed Series A investment round, aimed at funding the advancement of its two pioneering treatments, AT-001 and AT-004. 

Together, these examples show how AI is moving from promise to practice in health tech, enabling earlier diagnosis, more personalised treatments and smarter care delivery. For innovators across the EIC Scaling Club, AI is not just a tool, but a catalyst for breakthroughs with the potential to transform patient outcomes and whole healthcare systems.

About the EIC Scaling Club

The EIC Scaling Club is a curated community where 120+ European deep tech scale-ups with the potential to build world-class businesses and solve major global challenges come together with investors, corporate innovators and other industry stakeholders to spur growth.

The top 120+ European deep tech companies will be carefully selected from a pool of high-growth scale-ups that have benefitted from EIC financial schemes, other European and national innovation programmes, and beyond.

The EIC Scaling Club is an EIC-funded initiative run in partnership by Tech Tour, Bpifrance (EuroQuity), Hello Tomorrow, Tech.eu (Webrazzi), EurA and IESE Business School.

Subscribe to our newsletter here to stay up-to-date!